We provide you with 20 years of free, institutional-grade data for OMER stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of OMER. Explore the full financial landscape of OMER stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$87,039
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Cable Thomas J. | Sale | -7,500 | $11.61 | $87,039 | 2026-05-27 |
| Cable Thomas J. | Derivatives Exercise | 7,500 | 2026-05-27 | ||
| Demopulos Gregory A MD | Sale | -357,678 | $11.93 | $4,267,099 | 2026-02-20 |
| Demopulos Gregory A MD | Derivatives Exercise | 400,000 | 2026-02-20 | ||
| Borges David J. | Derivatives Exercise | 30,000 | 2026-01-14 | ||
| Borges David J. | Sale | -60,000 | $12.72 | $763,200 | 2026-01-14 |
| Borges David J. | Initial | 2024-07-03 | |||
| Demopulos Gregory A MD | Open Market Purchase | 15,000 | $1.68 | 2023-11-21 | |
| Demopulos Peter A MD | Open Market Purchase | 10,000 | $1.53 | 2023-11-17 | |
| Demopulos Gregory A MD | Grant, award...etc | 62,500 | $1.29 | 2023-11-15 | |
| Bumol Thomas F. | Grant, award...etc | 10,000 | $3.31 | 2023-09-14 | |
| HANISH ARNOLD C | Sale | -5,000 | $6.46 | $32,300 | 2023-05-23 |
| HANISH ARNOLD C | Derivatives Exercise | 5,000 | 2023-05-23 | ||
| Cable Thomas J. | Sale | -5,000 | $6.53 | $32,650 | 2023-05-23 |
| Cable Thomas J. | Derivatives Exercise | 5,000 | 2023-05-23 | ||
| HANISH ARNOLD C | Derivatives Exercise | 10,000 | 2021-09-09 | ||
| Demopulos Gregory A MD | Sale | -73,713 | $15.02 | $1,107,169 | 2021-06-17 |
| Demopulos Gregory A MD | Derivatives Exercise | 73,713 | 2021-06-17 | ||
| Demopulos Gregory A MD | Sale | -73,713 | $17.07 | $1,258,281 | 2021-05-21 |
| Demopulos Gregory A MD | Derivatives Exercise | 73,713 | 2021-05-21 | ||
| Demopulos Gregory A MD | Sale | -72,613 | $17.91 | $1,300,499 | 2021-04-08 |
| Demopulos Gregory A MD | Derivatives Exercise | 72,613 | 2021-04-08 | ||
| Demopulos Peter A MD | Derivatives Exercise | 10,000 | 2021-02-23 | ||
| JACOBSEN MICHAEL A | Sale | -18,100 | $22.64 | $409,784 | 2021-02-23 |
| JACOBSEN MICHAEL A | Derivatives Exercise | 18,100 | 2021-02-23 | ||
| Hood Leroy E. MD PhD | Derivatives Exercise | 5,000 | 2021-02-17 | ||
| JACOBSEN MICHAEL A | Sale | -1,900 | $22.49 | $42,731 | 2021-02-12 |
| JACOBSEN MICHAEL A | Derivatives Exercise | 1,900 | 2021-02-12 |
The information provided in this report about OMER stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Omeros Corporation(NASDAQ:OMER) 
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. ...
Website: http://www.omeros.com
Founded: 1994
Full Time Employees: 258
Sector: Healthcare
Industry: Biotechnology